Minerva Neurosciences (NASDAQ:NERV) Price Target Lowered to $7.00 at HC Wainwright

Minerva Neurosciences (NASDAQ:NERV) had its price target decreased by analysts at HC Wainwright from $11.00 to $7.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 186.89% from the company’s previous close.

Separately, StockNews.com downgraded shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Friday, February 23rd.

Minerva Neurosciences Stock Up 1.7 %

Minerva Neurosciences stock traded up $0.04 during mid-day trading on Thursday, reaching $2.44. 5,782 shares of the company’s stock traded hands, compared to its average volume of 95,832. The company has a market cap of $17.06 million, a price-to-earnings ratio of -0.51 and a beta of 0.27. The stock has a 50 day moving average of $2.85 and a two-hundred day moving average of $5.35. Minerva Neurosciences has a 12-month low of $2.29 and a 12-month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.31). As a group, sell-side analysts forecast that Minerva Neurosciences will post -3.57 earnings per share for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.